Novartis Reports Topline Data from P-III (V-MONO) Trial of Leqvio (Inclisiran) in Patients at Atherosclerotic Cardiovascular Disease (ASCVD) Risk
Shots:
- The 6mos. P-III (V-MONO) trial assesses the efficacy of twice-yearly Leqvio alone (n=174) vs PBO (n=87) & ezetimibe (n=89) among patient at low or moderate ASCVD risk, not on lipid-lowering therapy. The 1EPs included percent change in LDL-C at D150
- Study reached its 1EPs, significantly lowering LDL-C. These results will be highlighted at future conferences and shared with regulatory bodies, incl the US FDA
- Novartis is advancing Leqvio in the VICTORION-1-PREVENT (V1P) study for high-risk primary prevention that will complete enrollment in H2’24; the ORION-4 & VICTORION-2-PREVENT (V2P) studies for secondary prevention are underway, with results expected in 2026 & 2027, respectively
Ref: Novartis | Image: Novartis
Related Post:- Novartis Reports Results from the P-IIIb (V-INITIATE) Study of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
